Comparison of Buprenorphine with Morphine in post-operative pain after orthopedic surgeries.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012101311102N1

Enrollment

Registered

2013-07-24

Start date

2013-08-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopedic Surgeries. Fractures involving multiple regions of upper limb(s) with lower limb(s)

Interventions

Intervention 1: In the Morphine group , 0.2 mg kg as intravenous Morphine (maximum ten mg) is administered before induction of anesthesia. Intervention 2: In Buprenorphine group , 4.5 mcg/ kg Buprenor

Prevention

In the Morphine group , 0.2 mg kg as intravenous Morphine (maximum ten mg) is administered before induction of anesthesia.

In Buprenorphine group , 4.5 mcg/ kg Buprenorphine (up to a 1 mg)Prescribed as sublingual , half-hour before induction of anesthesia.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Orthopedic surgery(closed reduction-Pinning); Duration of surgery between thirty minutes to one hundred and twenty minutes; Over 18 years of age; ASA class I,II Exclusion criteria: Previous hypersensitivity to Buprenorphine and Morphine; History of analgesic use in the past 24 hours; Duration of surgery less than thirty minutes and more than one hundred and twenty minutes; Pregnant and lactating women; Addiction to Narcotic or Alcohol or Benzodiazepines.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Postoperative pain. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: VAS scale.	—

Secondary

Measure	Time frame
Nausea. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: Clinical evaluation and patient complaints.;Vomiting. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: Clinical evaluation and patient complaints.;Itching. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: Clinical evaluation and patient complaints.;Urinary retention. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: Clinical evaluation and patient complaints.	—

Measure

Time frame

Nausea. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: Clinical evaluation and patient complaints.;Vomiting. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: Clinical evaluation and patient complaints.;Itching. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: Clinical evaluation and patient complaints.;Urinary retention. Timepoint: Entry to recovery-30 minutes later-3hours later-6hours later-12hours later. Method of measurement: Clinical evaluation and patient complaints.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ghasem Soltani

Mashhad University of Medical Science, Emam Reza hospital

SoltaniGh@mums.ac.ir+98 51 1802 2711

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026